Art

J-GLOBAL ID：201902218331371406   Reference number：19A1280438

Translocation-Related Sarcomas

転移関連肉腫【JST・京大機械翻訳】

Author (2)： Nakano Kenji (Department of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-0063, Japan) ,  Takahashi Shunji (Department of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-0063, Japan)
Material： International Journal of Molecular Sciences (Web)  (Int J Mol Sci (Web))
Volume： 19  Issue： 12  Page： 3784  Publication year： 2018 
JST Material Number： U7038A  ISSN： 1422-0067  CODEN： IJMCFK  Document type： Article
Article type： 文献レビュー  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： Chromosomal translocations are...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A1280438&from=J-GLOBAL&jstjournalNo=U7038A") }}

Thesaurus term： alkylating agent ,  fusion protein ,  transcription factor ,  carcinogenicity ,  *sarcoma ,  tumor ,  Ewing sarcoma ,  molecular target therapy ,  tyrosine kinase ,  translocation(genetics) ,  gene
Semi thesaurus term： 臨床評価 ,  予後因子 ,  病理検査 ,  軟部組織肉腫 , 【Automatic Indexing@JST】

Author keywords (8)： Soft tissue sarcoma ,  chromosomal translocation ,  translocation-related sarcoma ,  Ewing sarcoma breakpoint region 1 ,  forkhead box transcription factor O ,  transcription factor E3 ,  anaplastic lymphoma kinase ,  neurotrophic tyrosine kinase

JST classification (5)： Biological function  (EB03040U) ,  Chemistry,biochemistry and pathology of tumors(=neoplasms)  (GE02030N) ,  Nucleic acids in general  (EB04010U) ,  Basic oncology in general  (GE02010R) ,  Wheats and barleys  (FC03033M)

Reference (136)：

• Rowley, J.D.; Le Beau, M.M.; Rabbitts, T.H. Chromosomal Translocations and Genome Rearrangements in Cancer; Springer: Cham, Switzerland, 2015; pp. 3-14. ISBN 978-3-319-19982-5.
• Schiffer, C.A. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N. Engl. J. Med. 2007, 357, 258-265.
• Soda, M.; Choi, Y.L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448, 561-566.
• Solomon, B.J.; Mok, T.; Kim, D.W.; Wu, Y.L.; Nakagawa, K.; Mekhail, T.; Felip, E.; Cappuzzo, F.; Paolini, J.; Usari, T.; et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014, 371, 2167-2177.
• Shaw, A.T.; Kim, T.M.; Crinò, L.; Gridelli, C.; Kiura, K.; Liu, G.; Novello, S.; Bearz, A.; Gautschi, O.; Mok, T.; et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017, 18, 874-886.

Terms in the title (1)： 肉腫